Nathaniel spent years learning the MedTech maze. His homepage sells 12 modules and hides him.

Every day we run one project building in public through Hivemind, the strategy engine Myosin uses with clients.

Today: NJB Startup Navigator (startup.njb-berky.com), an AI platform for MedTech and BioTech founders.

Start with your own bio, because it is stronger than your entire product page. Nathaniel, you wrote: "I spent years helping startups navigate EU MDR, IVDR, Swiss nDSG, and DACH market entry, and I got tired of watching brilliant founders, especially from India, lose months or years in the regulatory maze." That is a real expert and a real, expensive enemy. Then your product describes itself as "a multi-paradigm intelligence stack" and "12 modules in one workspace," which is the exact generic-AI-wrapper language you swear it is not. You buried the two things nobody can copy, you and the maze, under the one thing anyone can, a feature list.

Here is the tension. Your decade of hard-won regulatory judgment is being sold as a dashboard, which makes the one thing a competitor cannot replicate, Nathaniel, look like the one thing they can, software. A well-funded team can vibe-code twelve modules in a quarter. They cannot code the years you spent watching exactly where MedTech startups misclassify and die. When your page leads with modules, you invite a tool comparison you do not need to be in. When it leads with you, there is no comparison, because there is only one of you.

The lens is own the enemy, and the enemy is not a competitor. It is the MedTech regulatory maze: the twelve-to-eighteen-month compliance black hole where a startup misclassifies under MDR or IVDR, burns its runway on the wrong pathway, and dies before it ever reaches a patient or a buyer. That system was built for pharma giants and it punishes small teams who walk in without a guide. Every MedTech founder aiming at the EU has either lived that fear or is lying awake about it. You are the guide. Three moves, aimed at the founders in the maze right now.

Move 1: Make Nathaniel the product and the platform the delivery. Kill "multi-paradigm intelligence stack" from every surface today. Lead with your name, your actual credentials, EU MDR and IVDR, Swiss nDSG, DACH entry, and one concrete story of a founder you watched lose eighteen months. In a field where wrong regulatory advice means a costly compliance failure, the trust signal is the human, not the tech. This week: rewrite the hero and the IH description around one sentence a founder would say out loud, "I need to know my MDR classification before I burn another quarter."

Move 2: Beachhead on the regulatory roadmap, let the other eleven modules be expansion. Health score, investor match, grants, and pitch readiness are real, but they are generic enough for a funded competitor to clone in a quarter. The MDR and FDA pathway is where your expertise compounds into something nobody can weekend-build, because every founder you run through it adds to a case library of classification edge cases, failure points by vertical, and country-specific traps. That library is the moat. This week: hand five MedTech startups currently in the MDR or FDA pipeline free access to the roadmap module for thirty days, in exchange for a thirty-minute call with you personally. Five real users on the one module will teach you more than five hundred signups across twelve.

Move 3: Name the maze in everything you publish, and gather the tribe. Your audience is a small, specific, high-value group: MedTech founders targeting EU and DACH entry who know the maze is coming and are scared of it. Do not write thought leadership, write war stories from inside the maze. This week: post one piece titled something like "Your MDR classification is probably wrong, here is why," with one specific, named trap, and put it in front of three MedTech founder communities. The goal is not reach, it is five direct messages that say "this is exactly my problem."

One honest risk, and it is bigger than positioning. MedTech regulatory guidance is high-stakes, and a wrong MDR classification is not a small bug, it is a compliance failure that can end a startup, and if a founder asks your navigator a question and gets a wrong answer, it is your name that burns, not the product's. So the hedge is not optional: every regulatory output should carry your judgment, not the platform's voice. Not "the platform recommends," but "Nathaniel's assessment, based on these specific criteria." The AI accelerates your analysis, it does not replace it, and if the product cannot yet deliver that expert-in-the-loop review, that is the first thing to build, before a single new module.

And the question the whole strategy rests on: are you willing to be the product? To put your name on the outputs, post the war stories, take the founder calls? Because if you hide behind the platform, the one uncopyable asset you have goes unused, and this becomes another AI wrapper in a vertical that eats wrappers alive. The maze made you valuable. Do not let a dashboard hide it.

To Nathaniel: you already wrote the sharp version, it is your own bio. Put the expert and the maze on the page, and let the twelve modules be how you deliver, not what you sell.

Anyone else want their project run through the same lens? Reply with a link.